These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 37352112)

  • 21. The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population.
    Law W; Johnson C; Rushton M; Dent S
    Curr Oncol; 2017 Oct; 24(5):e348-e353. PubMed ID: 29089804
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cardiovascular events and risk factors in hematological neoplasms patients treated with anthracyclines].
    Dai MY; Zhang YL; Sun YX; Lyu X; Zhang XX; Sun XL; Fang FQ; Liu JW; Xia YL; Liu Y
    Zhonghua Xin Xue Guan Bing Za Zhi; 2022 Nov; 50(11):1058-1063. PubMed ID: 36418272
    [No Abstract]   [Full Text] [Related]  

  • 23. Risk profiles and incidence of cardiovascular events across different cancer types.
    Mitchell JD; Laurie M; Xia Q; Dreyfus B; Jain N; Jain A; Lane D; Lenihan DJ
    ESMO Open; 2023 Dec; 8(6):101830. PubMed ID: 37979325
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Global longitudinal strain at 3 months after therapy can predict late cardiotoxicity in breast cancer.
    Liu Z; Liu M; Zhong X; Qin Y; Liang T; Luo T; Yan X; Tang Z; Wang X; Liang S; Li Q; Ruan X; He W; Huang H
    Cancer Med; 2023 Jun; 12(12):13374-13387. PubMed ID: 37183826
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardio-Oncology: A New Discipline in Medicine and Its Relevance to Hematology.
    Spannbauer A; Bergler-Klein J
    Hamostaseologie; 2024 Aug; 44(4):255-267. PubMed ID: 38723641
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiac safety of non-anthracycline trastuzumab-based therapy for HER2-positive breast cancer.
    Yu AF; Mukku RB; Verma S; Liu JE; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Breast Cancer Res Treat; 2017 Nov; 166(1):241-247. PubMed ID: 28710537
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cardiovascular Burden and Adverse Events in Patients With Esophageal Cancer Treated With Chemoradiation for Curative Intent.
    Søndergaard MMA; Nordsmark M; Nielsen KM; Poulsen SH
    JACC CardioOncol; 2021 Dec; 3(5):711-721. PubMed ID: 34988480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of Cardiovascular Disease Risk Factors with Late Cardiotoxicity and Survival in HER2-positive Breast Cancer Survivors.
    He X; Ji J; Dai X; Qdaisat AZ; Esteva FJ; Hortobagyi GN; Yeung SJ
    Clin Cancer Res; 2021 Oct; 27(19):5343-5352. PubMed ID: 34117035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cardiac risk stratification of breast cancer patients in a cardio-oncology clinic.
    Doukas PG; Patel RN; Venkatesh V; Khan SS; Baldridge A; Akhter N
    Breast Cancer Res Treat; 2021 Nov; 190(1):133-142. PubMed ID: 34390418
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Haematologic malignancies associated with clozapine
    Chrétien B; Lelong-Boulouard V; Chantepie S; Sassier M; Bertho M; Brazo P; Humbert X; Alexandre J; Fedrizzi S; Dolladille C
    Psychol Med; 2021 Jul; 51(9):1459-1466. PubMed ID: 32036793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse Cardiovascular Effects of Anti-tumor Therapies in Patients With Breast Cancer: A Single-center Cross-sectional Analysis.
    Rosenkaimer S; Sieburg T; Winter L; Mavratzas A; Hofmann WK; Hofheinz RD; Akin I; Duerschmied D; Hohneck A
    Anticancer Res; 2022 Jun; 42(6):3075-3084. PubMed ID: 35641278
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
    Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
    Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease.
    Drafts BC; Twomley KM; D'Agostino R; Lawrence J; Avis N; Ellis LR; Thohan V; Jordan J; Melin SA; Torti FM; Little WC; Hamilton CA; Hundley WG
    JACC Cardiovasc Imaging; 2013 Aug; 6(8):877-85. PubMed ID: 23643285
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of primary haematologic cancers following incident non-metastatic breast cancer: A Danish population-based cohort study.
    Hjorth CF; Farkas DK; Schapira L; Cullen MR; Sørensen HT; Cronin-Fenton D
    Cancer Epidemiol; 2023 Feb; 82():102311. PubMed ID: 36508968
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Associations of heart failure to prevalence of haematologic- and solid malignancies in southern Sweden: A cross-sectional study.
    Scholten M; Halling A
    PLoS One; 2023; 18(10):e0292853. PubMed ID: 37831639
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Right Ventricular Ejection Fraction for the Prediction of Major Adverse Cardiovascular and Heart Failure-Related Events: A Cardiac MRI Based Study of 7131 Patients With Known or Suspected Cardiovascular Disease.
    Purmah Y; Lei LY; Dykstra S; Mikami Y; Cornhill A; Satriano A; Flewitt J; Rivest S; Sandonato R; Seib M; Lydell CP; Howarth AG; Heydari B; Merchant N; Bristow M; Fine N; Gaztanaga J; White JA
    Circ Cardiovasc Imaging; 2021 Mar; 14(3):e011337. PubMed ID: 33722059
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum Biomarkers to Dynamically Predict the Risk of Cardiovascular Events in Patients under Oncologic Therapy. A Multicenter Observational Study.
    Provinciali N; Piccininno M; Siri G; Gennari A; Antonucci G; Ricci D; Devoto E; Miceli R; Cortesi P; Pazzi C; Nanni O; Mannozzi F; Pastina I; Messuti L; Bengala C; Frassineti GL; Cattrini C; Fava M; Buttiron Webber T; Briata IM; Corradengo D; DeCensi A; Puntoni M
    Rev Cardiovasc Med; 2024 Jul; 25(7):256. PubMed ID: 39139415
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.